The Web Health

Subscribe

Paclitaxel protein-bound

Generic Name: Paclitaxel protein-bound [PAK-li-TAX-el-PRO-teen-bound].
The Brand Name: Abraxane.
Dosage Format: Intravenous powder for injection (100 mg).
Class of Drugs: Mitotic inhibitors.

What is paclitaxel protein bound?

Paclitaxel protein-bound is used to treat advanced cancer of the lung, breast, or pancreas. Paclitaxel protein-bound is employed to treat cancers that are not treated by surgical procedures or when other treatment options have not worked. Paclitaxel-protein-bound therapy is often offered along with other cancer drugs. Paclitaxel protein-bound can be used for other purposes not covered in this medication guideline.

Side effects of Paclitaxel protein-bound

Contact emergency medical assistance when you are experiencing symptoms warning signs of an allergic response (hives, breathing difficulties, or swelling of your throat or face) or a severe reaction to your skin (fever and throat soreness, eye burning, irritation, or red or purple itching, blisters, and peeling).

Paclitaxel protein-bound may cause serious side effects. Consult your doctor immediately. If you suffer from:

  • Numbness, tingling, pain, or a weakness in your feet or hands.
  • The sudden discomfort or pain in the chest or a rapid heart rate.
  • Dry throat, shortness of breath, shallow and rapid breathing.
  • Easily bleeding, unusual red or purple spots on your skin.
  • Low white blood cell counts—fever, oral sores and skin sores, cough, sore throat, difficulty breathing.
  • Red blood cells are low (anemia). pale skin sensation of fatigue, unusual tiredness sensation of lightheadedness or sluggish, cold hands and feet.
  • Signs of dehydration: headache, muscles, and dry mouth; thirst; dry and hot skin; vomiting; diarrhea; dark urine; inability to urinate.
  • A blood disease (sepsis)—fever, flu symptoms, oral and throat ulcers, rapid heart rate, slow breathing.

The treatment you receive for cancer could be delayed or completely stopped when you experience certain negative side effects.

Common negative side effects of paclitaxel bound to proteins include:

  • Symptoms of fever, chills, or other indications of infection.
  • Bruising, bleeding, and anemia.
  • Numbness, tingling, or swelling of your feet or hands.
  • Hair loss, rash.
  • The feeling of nausea, diarrhea, vomiting, and loss of appetite.
  • Irregular heartbeats.
  • Being tired.
  • Muscles and joint discomfort.
  • Abnormal liver function test results abnormal liver function tests.

This is not an exhaustive list of probable side effects, and others may arise. Consult your physician to seek medical advice on the effects. You can report any side effects to the FDA at 1-800-FDA-1088.

Warnings

It is not recommended to treat with paclitaxel-bound protein when you have a low white blood cell count.

Before you take this drug

You shouldn't be treated with this medication if you are sensitive to paclitaxel or if you suffer from

  • Low white blood cell count.
  • Serious liver disease that is severe.

Tell your doctor immediately if you have ever suffered from:

  • Liver disease.
  • kidney disease.
  • An allergic reaction to drugs such as paclitaxel protein bound (such as cabazitaxel and docetaxel).

Paclitaxel protein-bound may harm a newborn baby if either the father or mother is taking this medication.

  • If you're pregnant, do not use paclitaxel-protein-bound therapy. You might need to undergo a pregnancy test that is negative prior to beginning this treatment. Utilize effective contraception to stop the possibility of pregnancy while using this medication and at least six months after the last dose.
  • If you're male, use effective birth control if you are a partner with a sex who is capable of becoming pregnant. Use birth control for at least three months after your last dose.
  • Contact your physician immediately. If you become pregnant during the time that one of the parents or father is taking paclitaxel-bound

This medicine can impact fertility (the ability to bear children) for both men and women. It is nevertheless important to use birth control in order to stop pregnancy since paclitaxel protein binding could harm the unborn baby. Avoid breastfeeding while taking this medication. Do so for a minimum of two weeks after the last dose. Paclitaxel protein is produced from human plasma donated to the lab and could contain viruses and different infectious agents. Plasma donated is tested and treated to lower the risk of contamination; however, there is a chance that it could be a carrier of the disease. Consult your physician about the possibility of risks.

How to take paclitaxel protein bound?

Paclitaxel protein is administered as an injection into the vein. Your healthcare provider will offer the injection. To treat women with breast cancer Paclitaxel-protein-bound therapy is generally administered every three weeks. To treat lung cancer or pancreas This medication is administered as part of a 21- or 28-day treatment cycle. This medicine is available only on specific days in each cycle.

Your doctor will decide the length of time you will be treated with this medication. Inform your healthcare provider if you feel any pain, burning, or swelling in the area of your IV needle while the protein-bound paclitaxel is administered. There is a possibility that you will require regular medical tests to ensure that this medication does not cause adverse side effects. The treatment for cancer may be delayed depending on the results. There may be another medication to prevent any allergic reactions. Use this medication as long as your physician prescribes it.

Details on dosage

Usual Adult Dose for Breast Cancer:

250 mg/m2 IV in 30 minutes, at least every 3 weeks
Use: To treat patients with metastatic breast cancer following failing combination chemotherapy for metastatic disease or relapse after 6 months after the adjuvant treatment; previous treatment should include an anthracycline, unless contraindicated by a physician.

Usual Adult Dose for Non-Small Cell Lung Cancer:

100 mg/m2 intravenously over 30 minutes on Days 1, 15, 8, and 13 of each 21-day cycle. Give carboplatin on Day 1 of every 21-day cycle, right after paclitaxel protein-bound
Use: To treat localized metastatic or locally advanced NSCLC (NSCLC) as the first-line treatment with carboplatin for patients who aren't suitable for surgery, curative therapy, or radiation therapy.

Usual Adult Dose for Pancreatic Cancer:

250 mg/m2 IV for 30 to 40 minutes on days 1, 15, and 8 of each 28-day cycle. Apply gemcitabine immediately following the paclitaxel-bound protein on days 1, 8, and 15 of each 28-day cycle.
Use: To treat metastatic adenocarcinoma of the pancreas as a first-line treatment when combined with gemcitabine.

What happens if I miss a dose?

Contact your physician for advice in the event that you don't make an appointment for your paclitaxel protein-bound injection.

What happens if I overdose?

Get medical attention in an emergency or contact the Poison Help line toll-free at 1-800-222-1222.

What should be avoided?

Paclitaxel protein-bound is dangerous if it is in the eyes, mouth, nose, or even on your skin. If you get skin contact, clean the area with soap and water, or clean your eyes thoroughly with pure water.

Interaction with other drugs

Other medications can alter the paclitaxel protein binding. This includes medications that are prescribed and available over the counter, vitamins, and herbal products. Inform your physician about the medicines you are currently taking and any medications you begin or stop taking.